Ligand Pharma (LGND) PT Lowered to $140 at Argus, Weakness Offers Buying Opportunity
Tweet Send to a Friend
Argus analyst Jasper Hellweg lowered the price target on Ligand ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
